Update shared on05 Sep 2025
Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90.
Analyst Commentary
- Ongoing execution challenges in the MedTech segment are impacting overall group momentum.
- Analysts anticipate a slowdown in organic growth to around 5% for 2025.
- Recovery in orthopedics is required for a return to double-digit growth rates.
- Price target reductions reflect these weaker growth projections.
- Overall sentiment has shifted more cautious due to continued operational headwinds.
What's in the News
- CEO Patrik Eriksson stepped down; CFO Carl-Johan Zetterberg Boudrie appointed interim CEO while a search for a new CEO is initiated.
- Extraordinary General Meeting resolved to adopt new Articles of Association, introducing reclassifiable and redeemable share classes for the company's incentive program.
Valuation Changes
Summary of Valuation Changes for Vimian Group
- The Consensus Analyst Price Target remained effectively unchanged, at SEK38.90.
- The Future P/E for Vimian Group has significantly risen from 23.95x to 265.58x.
- The Discount Rate for Vimian Group remained effectively unchanged, moving only marginally from 5.96% to 5.95%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.